AbCellera Biologics Future Growth
Future criteria checks 2/6
AbCellera Biologics's earnings are forecast to decline at 13.5% per annum while its annual revenue is expected to grow at 22.6% per year. EPS is expected to decline by 8.8% per annum.
Key information
-13.5%
Earnings growth rate
-8.8%
EPS growth rate
| Life Sciences earnings growth | 16.8% |
| Revenue growth rate | 22.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 21 May 2024 |
Recent future growth updates
Recent updates
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
May 29
AbCellera: Cash Providing Shelter From Market Weakness
May 16AbCellera: Victim Of Its Own Success
Feb 28AbCellera Biologics: Continuing To Expand Partnerships
Feb 13Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?
Feb 04AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate
Nov 29AbCellera Biologics: Many Reasons To Own This Undervalued Stock
Sep 06AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
Aug 14AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
Aug 03AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
Jun 06Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
May 13Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%
May 07AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
Apr 22AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
Feb 11AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
Dec 05AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy
Oct 18AbCellera Biologics: I Was Wrong
Aug 20AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be
Aug 17AbCellera Biologics: A Buy At Current Prices
Aug 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 66 | -218 | N/A | N/A | 4 |
| 12/31/2025 | 52 | -215 | N/A | N/A | 8 |
| 12/31/2024 | 42 | -175 | N/A | N/A | 11 |
| 3/31/2024 | 36 | -147 | -128 | -42 | N/A |
| 12/31/2023 | 38 | -146 | -121 | -44 | N/A |
| 9/30/2023 | 50 | -129 | -69 | 7 | N/A |
| 6/30/2023 | 145 | -74 | -189 | -120 | N/A |
| 3/31/2023 | 181 | -50 | 60 | 133 | N/A |
| 12/31/2022 | 485 | 159 | 205 | 277 | N/A |
| 9/30/2022 | 603 | 248 | 160 | 230 | N/A |
| 6/30/2022 | 507 | 200 | 287 | 351 | N/A |
| 3/31/2022 | 489 | 205 | 166 | 235 | N/A |
| 12/31/2021 | 375 | 153 | 186 | 245 | N/A |
| 9/30/2021 | 444 | 177 | 212 | 263 | N/A |
| 6/30/2021 | 448 | 197 | 219 | 265 | N/A |
| 3/31/2021 | 431 | 203 | 120 | 133 | N/A |
| 12/31/2020 | 233 | 85 | 8 | 23 | N/A |
| 9/30/2020 | 28 | 0 | 8 | 22 | N/A |
| 6/30/2020 | 23 | 2 | 15 | 25 | N/A |
| 3/31/2020 | 14 | -3 | -7 | 0 | N/A |
| 12/31/2019 | 12 | -2 | -1 | 3 | N/A |
| 12/31/2018 | 9 | 0 | -2 | 4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABCL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABCL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABCL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABCL's revenue (22.6% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: ABCL's revenue (22.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ABCL's Return on Equity is forecast to be high in 3 years time